Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Osteonecrosis of the jaws (ONJ) is a recognized complication of bisphosphonates (BP) therapy in cancer patients with bone metastasis. We report 2 additional cases of ONJ in women with breast cancer after long-term exposure to BP, discussing some considerations about the presentation and management of this rare and new complication.
Aguiar Bujanda
D
D
Servicio de Oncología Médica, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. dagubuj@gobiernodecanarias.org
Cabrera Suárez
M A
MA
Bohn Sarmiento
U
U
Quintero Pérez
S
S
Aguiar Morales
J
J
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007571:Jaw Diseases / Q000139:chemically induced*; D008408:Mastectomy; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*; D011878:Radiotherapy; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid